

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

Stakeholders raised the following equality issues:
--

- | |
|--|
| <ul style="list-style-type: none">• Obicetrapib and obicetrapib–ezetimibe could be used in people who do not meet the criteria to start PCSK9 inhibitors, icosapent ethyl or bempedoic acid• An additional oral medicine would be useful for people who may not want injectable treatments because of storage/administration issues and/or needle phobias• Secondary prevention is mainly carried out in primary care. Limiting prescribing to secondary care will limit implementation as there is not the capacity on secondary care services. |
|--|

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The committee will consider the potential equality issues raised during the appraisal process. Committee will consider the population and mode of administration in their decision making. Whilst committee consider implementation, it is not within their remit for decision making.
--

3.	Has any change to the draft scope been agreed to highlight potential equality issues?
No	

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No	

Approved by Associate Director (name):Lorna Dunning.....

Date: 15/12/2025